Latham & Watkins Advises CVC on $703 Million Acquisition of Theramex

Theramex is a global specialty pharmaceutical company dedicated to women and their health.

01 February 2018

Latham & Watkins advised CVC Capital Partners ("CVC") on CVC Fund VI's acquisition of Teva Pharmaceutical Industries Ltd’s international women's health assets. The transaction was agreed in Q3 2017 and closed on 1 February 2018.

The new company, called Theramex, is a global specialty pharmaceutical company dedicated to women and their health. Headquartered in London, UK, the company will market a broad range of innovative, branded and branded generic products across 50 countries around the world. The portfolio, which is dedicated to women's health, focuses on contraception, fertility, menopause and osteoporosis. 

Latham & Watkins represented CVC in the transaction with a London team led by corporate partner Robbie McLaren with associates Karima Salway, Emily Cridland, Samantha Peacock, Ei Nge Htut and Andria Varnavides. Advice was also provided on IP matters by partner Gail Crawford with associate Rachael Hammond; on separation and supply matters by associates Frances Stocks Allen and Terese Saplys; on regulatory matters by counsel Elizabeth Richards and associate Eitan Bernstein;  and on employment matters by associate Shaun Thompson.


 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.